Intelligence · Clinical Development
Pipeline search results
Programs matching “schizophrenia” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 97 pipeline programs matching "schizophrenia" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
1346-0014
Boehringer Ingelheim
Schizophrenia
1 trial -
ALKS 9072
Alkermes Pharma Ireland
Schizophrenia
1 trial -
ALKS 9072, Low Dose
Alkermes Pharma Ireland
Schizophrenia
1 trial -
Aripiprazole IM Depot
Otsuka Beijing Research Institute
Schizophrenia
1 trial -
Asenapine Sublingual Tablets 10 mg
Amneal Pharma Europe Ltd
Schizophrenia
1 trial -
Bifeprunox
H. Lundbeck A/S
Schizophrenia
1 trial -
Brilaroxazine
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Schizophrenia
1 trial -
CN0120020
Bristol-Myers Squibb Australia Pty Ltd
Schizophrenia
1 trial -
Iclepertin
Boehringer Ingelheim
Schizophrenia
2 trials -
LB-102
LB PHARMACEUTICALS INC
Schizophrenia
4 trials -
LB-102 (50 mg tablet)
LB PHARMACEUTICALS INC
Schizophrenia
1 trial -
Lu AF35700
H. Lundbeck A/S
Treatment-resistant Schizophrenia
1 trial -
NBI-1117568
NEUROCRINE BIOSCIENCES INC
Schizophrenia
5 trials -
NBI-1117568, NBI-1117568
NEUROCRINE BIOSCIENCES INC
Schizophrenia, Schizophrenia
1 trial -
NBI-1117568-SCZ3030
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial -
NBI-98854-ATS3019
NEUROCRINE BIOSCIENCES INC
Schizophrenia
1 trial -
NW-3509/023/III/2024
Lacuna Pharma Pty Ltd
treatment-resistant schizophrenia (TRS)
1 trial -
Paliperidone palmitate
Janssen Cilag International NV
Schizophrenia
2 trials -
Phase 1: Olanzapine
Shanghai Mental Health Center
Schizophrenia
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Schizophrenia
4 trials -
Placebo
Hoffmann-La Roche
Schizophrenia
1 trial -
Placebo
NEUROCRINE BIOSCIENCES INC
Schizophrenia
2 trials -
RBP-7000
Indivior Pty Ltd
Schizophrenia
5 trials -
RGH-188-203
Gedeon Richter Plc.
Adolescent patient (13-17 years of age) with Schizophrenia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.